Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.

Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E, Braue A, Scott R, Varigos G, Ferrao P, Ashman LK.

Br J Dermatol. 2008 Nov;159(5):1160-9. doi: 10.1111/j.1365-2133.2008.08827.x. Epub 2008 Sep 15.

PMID:
18795925
2.

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.

Exp Hematol. 2003 Aug;31(8):686-92.

PMID:
12901973
3.
4.

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.

Blood. 2004 Apr 15;103(8):3222-5. Epub 2003 Dec 24.

5.
6.

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.

Isotani M, Yamada O, Lachowicz JL, Tamura K, Yagihara H, Fujino Y, Ono K, Washizu T, Bonkobara M.

Br J Haematol. 2010 Jan;148(1):144-53. doi: 10.1111/j.1365-2141.2009.07926.x. Epub 2009 Oct 5.

PMID:
19804453
7.

[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].

Sotlar K.

Verh Dtsch Ges Pathol. 2007;91:169-76. German.

PMID:
18314612
8.

c-Kit and c-kit mutations in mastocytosis and other hematological diseases.

Boissan M, Feger F, Guillosson JJ, Arock M.

J Leukoc Biol. 2000 Feb;67(2):135-48. Review.

PMID:
10670573
9.

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA.

Br J Haematol. 2007 Jul;138(1):12-30. Review.

PMID:
17555444
11.

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Födinger M.

Br J Haematol. 2001 May;113(2):357-64.

PMID:
11380399
12.

Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.

Hartmann K, Wardelmann E, Ma Y, Merkelbach-Bruse S, Preussner LM, Woolery C, Baldus SE, Heinicke T, Thiele J, Buettner R, Longley BJ.

Gastroenterology. 2005 Sep;129(3):1042-6.

PMID:
16143141
13.

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.

Takeuchi Y, Fujino Y, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H.

Vet Immunol Immunopathol. 2010 Oct 15;137(3-4):208-16. doi: 10.1016/j.vetimm.2010.05.009. Epub 2010 May 31.

PMID:
20591500
14.

Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.

Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M.

Vet Immunol Immunopathol. 2006 Nov 15;114(1-2):168-72. Epub 2006 Sep 5.

PMID:
16908071
15.

Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects.

Nagata H, Worobec AS, Metcalfe DD.

Exp Clin Immunogenet. 1996;13(3-4):210-4.

PMID:
9165275
16.

Analysis of c-kit gene integrity in aplastic anemia.

Paquette RL, Hsu NC, Koeffler HP.

Blood Cells Mol Dis. 1996;22(2):159-68.

PMID:
8931956
17.

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.

Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P, Lackner H, Schwinger W, Benesch M, Urban C.

Blood. 2008 Sep 1;112(5):1655-7. doi: 10.1182/blood-2008-03-147785. Epub 2008 Jun 20.

18.

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Exp Hematol. 2010 Sep;38(9):782-91. doi: 10.1016/j.exphem.2010.05.004. Epub 2010 May 26.

PMID:
20685234
19.

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H.

Leuk Res. 2006 Nov;30(11):1365-70. Epub 2006 Jun 23.

PMID:
16797704
20.

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.

Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD.

Leuk Res. 2006 Apr;30(4):373-8. Epub 2005 Sep 22.

PMID:
16183119

Supplemental Content

Support Center